

Chenxing Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/105979/publications.pdf>

Version: 2024-02-01

11
papers

486
citations

1307594

7
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

969
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Characterization of AEBP1 at Transcriptional Level in Glioma. BioMed Research International, 2021, 2021, 1-16.	1.9	2
2	LTBP1 plays a potential bridge between depressive disorder and glioblastoma. Journal of Translational Medicine, 2020, 18, 391.	4.4	11
3	Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma. BioMed Research International, 2020, 2020, 1-8.	1.9	5
4	Depressive and anxiety disorders worsen the prognosis of glioblastoma. Aging, 2020, 12, 20095-20110.	3.1	11
5	Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy. Oncology Letters, 2019, 18, 6509-6515.	1.8	3
6	Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. Oncology Letters, 2016, 11, 1829-1834.	1.8	74
7	Classification based on mutations of <i>TERT</i> promoter and <i>IDH</i> characterizes subtypes in grade II/III gliomas. Neuro-Oncology, 2016, 18, 1099-1108.	1.2	93
8	Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases. Oncotarget, 2016, 7, 59098-59114.	1.8	10
9	Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. Oncotarget, 2016, 7, 80091-80100.	1.8	2
10	Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping. Neuro-Oncology, 2015, 17, 282-288.	1.2	151
11	IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget, 2015, 6, 40896-40906.	1.8	116